Published in Semin Oncol on March 01, 1985
Progesterone treatment for experimental stroke: an individual animal meta-analysis. J Cereb Blood Flow Metab (2013) 0.89
Light Antennas in phototactic algae. Microbiol Rev (1980) 3.40
A COENZYME CONTAINING PSEUDOVITAMIN B(12). Proc Natl Acad Sci U S A (1958) 2.80
Physiological disposition and metabolism of 5-(2',4'-difluorophenyl)salicyclic acid, a new salicylate. Drug Metab Dispos (1976) 2.23
Oligopeptide uptake by Bacteroides ruminicola. J Bacteriol (1967) 1.98
High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother (1987) 1.94
Improved reagent for trimethylsilylation of sphingolipid bases. J Lipid Res (1967) 1.90
Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob Agents Chemother (1980) 1.85
Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrob Agents Chemother (1979) 1.69
Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther (1991) 1.58
Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine. J Infect Dis (1994) 1.55
Linkage of six genes in Chlamydomonas reinhardtii and the construction of linkage test strains. J Bacteriol (1975) 1.54
Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother (1992) 1.53
Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol (2007) 1.47
Phase I study of multiple-dose cefprozil and comparison with cefaclor. Antimicrob Agents Chemother (1990) 1.33
Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor. Antimicrob Agents Chemother (1990) 1.32
Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother (1990) 1.32
Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther (1990) 1.32
Phase I study of single-dose BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother (1990) 1.27
Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol (2001) 1.24
Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide. J Pharm Sci (1980) 1.24
Gastric alkalinization. Effect on lower-esophageal-sphincter pressure and serum gastrin. N Engl J Med (1974) 1.20
Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob Agents Chemother (1990) 1.17
Bioavailability and metabolism of potassium phosphanilate in laboratory animals and humans. Antimicrob Agents Chemother (1980) 1.14
Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab Dispos (1991) 1.13
Impaired host resistance to endotoxin and malaria in polychlorinated biphenyl- and hexachlorobenzene-treated mice. Infect Immun (1978) 1.11
Pharmacokinetics of methyldopa in man. J Pharmacol Exp Ther (1976) 1.10
Chemistry and metabolism of sphingolipids. 3-Oxo derivatives of N-acetylsphingosine and N-acetyldihydrosphingosine. J Am Chem Soc (1966) 1.10
Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells. Clin Exp Immunol (2009) 1.08
Polychlorinated biphenyl and hexachlorobenzene induced humoral immunosuppression. J Reticuloendothel Soc (1977) 1.05
Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians (2000) 1.04
Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. J Pharmacokinet Biopharm (1976) 1.03
Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol (1985) 1.02
Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects. J Clin Pharmacol (1990) 1.01
Pharmacokinetics and metabolism of hexachlorobenzene in the rat and the rhesus monkey. J Agric Food Chem (1978) 1.00
Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol (1990) 0.97
High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr (1993) 0.95
Hypothyroidism following removal of a "thyroglossal duct cyst". Plast Reconstr Surg (1981) 0.95
Effects of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother (1992) 0.95
Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys. Antimicrob Agents Chemother (1987) 0.93
Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J Clin Pharmacol (1992) 0.93
Genetic investigation of a negatively phototactic strain of Chlamydomonas reinhardtii. Genet Res (1985) 0.93
Disposition of 14C-cefatrizine in man. Drug Metab Dispos (1980) 0.92
Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents. Antimicrob Agents Chemother (1982) 0.91
An enhanced postnatal autoimmune profile in 24 week-old C57BL/6 mice developmentally exposed to TCDD. Toxicol Appl Pharmacol (2008) 0.91
Equine degenerative myeloencephalopathy in Lusitano horses. J Vet Intern Med (2011) 0.91
Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J Clin Pharmacol (1992) 0.90
Calcium stimulation of gastrin and gastric acid secretion: effect of small doses of calcium carbonate. Gut (1977) 0.89
Impact of different cell isolation techniques on lymphocyte viability and function. J Immunoassay Immunochem (2006) 0.88
Change in flagellar beat frequency of Chlamydomonas in response to light. Prog Clin Biol Res (1982) 0.88
Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol (1991) 0.87
Temporal pattern and reversal of impaired hepatic mono-oxygenases by phenobarbital in rats with developing and established adjuvant disease. J Pharmacol Exp Ther (1977) 0.87
Pharmacokinetics and tolerability of suprofen. Experience with intramuscular application in healthy volunteers. Arzneimittelforschung (1985) 0.86
Comparative tissue distribution of ceforanide, cefazolin, and cefamandole in rats. Antimicrob Agents Chemother (1981) 0.86
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer (1991) 0.86
Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer (1992) 0.86
Clinical pharmacokinetics of carboplatin. J Clin Pharmacol (1988) 0.86
Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine. Antimicrob Agents Chemother (1983) 0.85
Pharmacokinetics of pentazocine in the rhesus monkey. J Pharm Sci (1974) 0.85
Diflunisal renal clearance in anesthetized dogs: effect of probenecid, urine flow, and urine pH. Arch Int Pharmacodyn Ther (1978) 0.84
Androgens and penile erection: a review. J Androl (1997) 0.84
Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther (1991) 0.84
Environmental chemical-induced immune dysfunction. Ecotoxicol Environ Saf (1978) 0.84
High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr (1991) 0.84
Metabolism in vitro and in vivo of pentazocine. Biochem Pharmacol (1969) 0.83
Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol (1985) 0.82
Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment. J Clin Pharmacol (1991) 0.82
Carrageenan: the effect of molecular weight and polymer type on its uptake, excretion and degradation in animals. Food Cosmet Toxicol (1976) 0.82
The relationship between serum gastrin, gastric ulceration and basal acid output in the polyarthritic rat. J Pharmacol Exp Ther (1980) 0.82
Methaqualone pharmacokinetics after single- and multiple-dose administration in man. J Pharmacokinet Biopharm (1974) 0.81
[The effect of cimetidine on the metabolism and effects of alcohol]. Arzneimittelforschung (1984) 0.81
Ceforanide kinetics in renal insufficiency. Clin Pharmacol Ther (1981) 0.81
Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Cephalalgia (2012) 0.81
Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1992) 0.81
Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in man. J Pharmacokinet Biopharm (1978) 0.81
Induction of hepatic enzymes by methaqualone and effect on warfarin-induced hypoprothrombinemia. J Pharmacol Exp Ther (1976) 0.81
High-performance liquid chromatographic analysis of a novel carbapenem antibiotic in human plasma and urine. J Chromatogr (1987) 0.81
Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol (1992) 0.81
Effect of food on the bioavailability of gepirone in humans. J Clin Pharmacol (1993) 0.81
Liquid chromatographic procedure for the quantitative analysis of megestrol acetate in human plasma. J Pharm Sci (1985) 0.80
Human pharmacokinetics and disposition of sarmoxicillin, a lipophilic amoxicillin prodrug. Antimicrob Agents Chemother (1981) 0.80
A novel branched-chain sphingolipid base from Crithidia fasciculata. Biochem Biophys Res Commun (1966) 0.80
Branched-chain sphingosines from Tetrahymena pyriformis. Biochem Biophys Res Commun (1967) 0.80
Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog. Drug Metab Dispos (1993) 0.79
Disposition of parenteral butorphanol in man. Drug Metab Dispos (1980) 0.79
Mirex kinetics in the rhesus monkey. I. Disposition and excretion. Drug Metab Dispos (1976) 0.79
Sensitive high-performance liquid chromatographic method for the determination of chlorhexidine in human serum and urine. J Chromatogr (1986) 0.78
Lack of pharmacokinetic interaction between cefepime and amikacin in humans. Antimicrob Agents Chemother (1992) 0.78
Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog, and rat. Drug Metab Dispos (1979) 0.78
Mirex kinetics in the rhesus monkey. II. Pharmacokinetic model. Drug Metab Dispos (1976) 0.78
The site of gastrointestinal absorption of gepirone in humans. J Clin Pharmacol (1992) 0.78
Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharm Drug Dispos (1993) 0.78
Ethanol impact on brain acetylcholine and its modification by cysteine. Arch Int Pharmacodyn Ther (1967) 0.78
The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol. Eur J Clin Pharmacol (1994) 0.77
Biochemical studies on the resolution of experimental inflammations in animals treated with bromelain. Exp Med Surg (1967) 0.77
Effect of antacid on the bioavailability of cefprozil. Antimicrob Agents Chemother (1992) 0.77
High-performance liquid chromatographic method for the quantitative determination of butorphanol, hydroxybutorphanol, and norbutorphanol in human urine using fluorescence detection. J Chromatogr (1994) 0.77
Biological disposition of 8-methoxsalen in rat and man. Arzneimittelforschung (1980) 0.77